Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seasonal influenza virus vaccine high dose - Sanofi Pasteur

Next Previous
Drug Profile

Seasonal influenza virus vaccine high dose - Sanofi Pasteur

Alternative Names: Fluzone HD; Fluzone® High Dose IM; Fluzone® High-Dose influenza vaccine; Seasonal influenza virus vaccine - sanofi

Latest Information Update: 08 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi pasteur
  • Developer Peter MacCallum Cancer Centre; Sanofi; Sanofi K.K.
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 10 Nov 2021 Phase-II clinical trials in Influenza virus infections (In adolescents, In children, In infants, In neonates), prior to November 2021 (IM) (Sanofi pipeline, November 2021)
  • 07 Sep 2020 Sanofi Pasteur plans a phase III trial for Influenza (In infants, In Children) in Australia, Brazil, Chile, Colombia, Czech Republic, Finland, Germany, Italy, Mexico, Philippines, Poland, South Africa, Spain, Taiwan and USA (IM) (EudraCT2019-004721-24)
  • 21 Apr 2020 Sanofi completes a phase II/III trial in Influenza virus infections (In adults, Prevention) in Australia (IM) (ACTRN12619000617167)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top